Insider Buying: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Acquires 43,707 Shares of Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Venrock Healthcare Capital Par bought 43,707 shares of the business’s stock in a transaction dated Thursday, January 30th. The stock was bought at an average price of $8.76 per share, for a total transaction of $382,873.32. Following the purchase, the insider now owns 4,986,480 shares in the company, valued at approximately $43,681,564.80. This represents a 0.88 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Monday, February 3rd, Venrock Healthcare Capital Par acquired 14,562 shares of KalVista Pharmaceuticals stock. The stock was purchased at an average cost of $9.22 per share, with a total value of $134,261.64.

KalVista Pharmaceuticals Stock Performance

KalVista Pharmaceuticals stock opened at $9.75 on Wednesday. KalVista Pharmaceuticals, Inc. has a one year low of $7.30 and a one year high of $16.88. The company has a 50-day simple moving average of $8.81 and a 200-day simple moving average of $10.77. The firm has a market capitalization of $481.85 million, a P/E ratio of -2.68 and a beta of 0.85.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.01. As a group, sell-side analysts forecast that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on KALV shares. TD Cowen assumed coverage on KalVista Pharmaceuticals in a research report on Tuesday, January 7th. They issued a “buy” rating and a $30.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, December 9th. Bank of America initiated coverage on shares of KalVista Pharmaceuticals in a report on Wednesday, December 18th. They set a “buy” rating and a $22.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of KalVista Pharmaceuticals in a report on Friday, December 6th. Finally, Citizens Jmp raised shares of KalVista Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 31st. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, KalVista Pharmaceuticals currently has an average rating of “Buy” and an average target price of $23.80.

Institutional Trading of KalVista Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in KALV. Vestal Point Capital LP grew its stake in shares of KalVista Pharmaceuticals by 73.9% in the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the specialty pharmaceutical company’s stock worth $46,320,000 after purchasing an additional 1,700,000 shares in the last quarter. State Street Corp grew its position in KalVista Pharmaceuticals by 68.1% in the 3rd quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company’s stock valued at $14,725,000 after buying an additional 515,179 shares in the last quarter. Emerald Advisers LLC increased its stake in KalVista Pharmaceuticals by 29.8% during the 3rd quarter. Emerald Advisers LLC now owns 835,988 shares of the specialty pharmaceutical company’s stock valued at $9,681,000 after buying an additional 192,091 shares during the period. Readystate Asset Management LP bought a new stake in shares of KalVista Pharmaceuticals during the 3rd quarter worth about $2,084,000. Finally, Emerald Mutual Fund Advisers Trust raised its position in shares of KalVista Pharmaceuticals by 23.0% during the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 650,980 shares of the specialty pharmaceutical company’s stock worth $7,538,000 after buying an additional 121,615 shares in the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).